Nifty ready to scale new highs on bullish mood: Analysts
The Nifty is expected to continue its bullish trend, potentially reaching all-time highs of 26,000-26,200 after breaking out of a consolidation phase. Analysts suggest a 'buy-on-dips' strategy, favoring sectors like banking, financials, and auto. Key support lies around 25,200, with potential resistance at 25,800, indicating a positive outlook for the market this week.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
The market is expected to maintain its bullish momentum this week, having broken out of a consolidation phase. According to technical analysts, the Nifty could gradually move towards its all-time high levels of 26,000–26,200, with initial resistance seen at 25,800. The 25,200 zone is now likely to act as a support base.HEAD – TECHNICAL AND DERIVATIVES RESEARCH, AXIS SECURITIESThe Nifty closed above the previous week's peak, indicating powerful upward momentum. Having broken free from its earlier trading range of 24,400–25,200, the index's recent close above 25,200 suggests potential for further advances. Nifty could soon test its record high of 26,277, and if it surpasses 25,800, we may see fresh buying interest that could drive it toward the 26,000–26,250 range. On the downside, a drop below 25,500 could result in retreating to 25,200–25,000 zone. The consistent rise in both daily and weekly RSI, remaining solidly above key thresholds, further emphasises the prevailing bullish sentiment.Traders can initiate a moderately bullish strategy with reduced premium outflow and a lower breakeven point called a 'Bull Call Spread' of 3rd July weekly expiry. In this net delta long strategy, traders need to buy one lot of the 25,700 Call strike at Rs 117 and simultaneously sell one lot of the 26,000 Call strike at Rs 29, so that the net outflow or maximum loss will be restricted to up to Rs 6,600. Nifty, on expiry, if it closes above 25,788, the strategy will start making a profit as it's the break-even point for the strategy.However, as the risk is limited, so is the profit. The maximum gains will be restricted to Rs 15,900, because the gains of a long 25,700 strike Call will be offset by the sold 26,000 strike Call if Nifty closes above 26,000 on expiry. Investors can focus on stocks like Bajaj Auto , Reliance, Hindustan Petroleum , Titan, Eicher Motors, Sun Pharma, Hindalco, and IndusInd Bank for potential opportunities.TECHNICAL ANALYST, ASIT C. MEHTA INVESTMENTNifty finally broke out of the consolidation range of 24,400–25,200, which persisted for over a month. The recent rally was driven by heavyweights such as the Banking index, Reliance Industries , and Bharti Airtel, supported by broad market participation. Going ahead, we expect the index to challenge its previous record high levels and advance towards the 26,000–26,200 zone. On the downside, 25,200 now acts as an important intermediate support, followed by 24,800.We remain optimistic on power stocks like Power Grid and Tata Power. The FMCG index also looks good as it has rebounded from crucial support; Hindustan Unilever and Nestlé are among the preferred picks. Realty stocks, after decent moves, are now showing signs of profi t booking. Select stocks like Bharat Forge, Hero MotoCorp, and Torrent Pharma are exhibiting strength on the charts and should be kept on the watchlist for tradingSVP – RESEARCH, RELIGARE BROKINGWith the Nifty ending its consolidation phase through a decisive breakout, we now expect a gradual move toward the all-time high of 26,277. However, the gap area around 25,800 could cause a temporary pause. In the event of a pullback, the 24,800–25,200 zone—which previously acted as resistance—is likely to offer strong support.Participants are advised to maintain a 'buy-on-dips' strategy with an emphasis on selective stock picking. We continue to favour rate-sensitive sectors such as banking, financials, auto, and real estate, while recommending a cautious and selective stance toward other sectors. Based on the current technical setup, the following stocks can be considered for short-term trading opportunities: Apollo Hospitals, Shriram Finance, UNO Minda, Hero MotoCorp, Hindustan Petroleum , ICICI Prudential Life, InterGlobe Aviation, Jubilant FoodWorks, Laurus Labs, UltraTech Cement, and Vedanta
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
42 minutes ago
- Hans India
Sensex, Nifty end lower after rising for 4 straight sessions
After rising for four straight sessions, the Indian stock markets took a breather on Monday as investors booked profits amid the absence of strong domestic cues. The Sensex dropped 452 points, or 0.54 per cent, to close at 83,606.46. During the day, it moved between an intra-day high of 84,099.53 and a low of 83,482.13. Nifty also followed suit. The 50-share index opened at 25,661.65, touched a high of 25,669.35, and closed at 25,517.05, down by 120.75 points or 0.47 per cent. In contrast, the broader markets performed better. The Nifty Midcap100 rose 0.6 per cent while the Nifty Smallcap100 gained 0.52 per cent -- indicating continued investor interest in mid- and small-cap stocks. Among the Sensex stocks, Axis Bank, Kotak Mahindra Bank, Maruti, Bajaj Finance, Reliance Industries, Tata Steel, and Bharti Airtel were among the top losers. On the gaining side, Trent, State Bank of India, Bharat Electronics, Titan, Bajaj Finserv, and Eicher Motors saw buying interest. Sector-wise, performance was mixed. PSU banks led the gains with the Nifty PSU Bank index jumping 2.66 per cent. Stocks like Maharashtra Bank, Punjab National Bank, Bank of Baroda, Union Bank of India, Canara Bank, UCO Bank, Indian Bank, and Punjab & Sind Bank recorded notable gains. Other sectors like IT, Consumer Durables, Pharma, Healthcare, Media, and Energy also ended in the green. However, some major sectors saw losses. Nifty Auto, Bank, Financial Services, FMCG, Metal, Realty, Private Bank, and Oil & Gas indices ended lower. Vinod Nair, Head of Research at Geojit Financial Services, said that while global sentiment is turning positive due to easing tensions in the Middle East and hopes of a US trade deal, Indian markets took a pause after the recent rally. He added that investors are now focusing on upcoming corporate earnings, with mid- and small-cap stocks showing strength in anticipation of better results driven by consumer demand and improved margins. Meanwhile, the India VIX, which measures market volatility, rose by 3.2 per cent to settle at 12.78. Rupee traded weak near 85.70, down by 0.21 per cent, as capital market weakness and recent rupee gains prompted profit booking and long unwinding. 'The pressure came ahead of a crucial week marked by key US data releases and the end of the 90-day extended tariff deadline. Rupee is expected to remain volatile within a range of 85.35 to 86.00," Jateen Trivedi of LKP Securities stated.
India Gazette
an hour ago
- India Gazette
Rural FMCG volume grew thrice urban volume growth in Q4FY25, similar trend likely to continue: Report
New Delhi [India], June 30 (ANI): Driven by increased distribution of freebies and a positive sentiment from good monsoon, rural market in India's fast-moving consumer goods (FMCG) sector continues to outperform urban areas, according to a recent report by Nuvama Institutional Equities. The report stated that rural markets continued to outpace urban areas in the overall FMCG sector. It noted that rural demand is already doing well and remains strong, while urban markets are facing pressure and are likely to stay under strain until the first half of FY26. However, urban demand is expected to start improving from the second half of FY26, the report stated. In terms of volume growth, rural regions have shown remarkable performance. For the fourth consecutive quarter, rural areas have grown more than twice as fast as urban regions. In Q4FY25, rural FMCG volumes grew by 8.4 per cent, while urban volume growth stood at 2.6 per cent, it said. The report also highlighted that the FMCG sector volumes in Q4FY25 saw rural growth being three times higher than urban areas. Initial data for Q1FY26 suggests a similar trend is likely to continue. Overall, the consumer sector grew 11 per cent year-on-year (YoY) by value in Q4FY25, compared to 10.6 per cent YoY in Q3FY25. Pricing growth was reported at 5.6 per cent, while overall volumes expanded by 5.1 per cent YoY, a slight decline from the 7.1 per cent YoY growth recorded in Q3FY25. Despite the positive performance in rural markets, the FMCG sector saw a significant selloff by foreign portfolio investors (FPIs) in the first half of June 2025. According to the report, FMCG recorded the highest outflows of Rs 36.3 billion, after receiving net inflows worth Rs 8.2 billion in May. Until May, the sector witnessed sales worth over Rs 140 billion. The report added that FPIs showed a strong inclination towards rate-sensitive and beta plays, contributing to the withdrawal from FMCG stocks. (ANI)
News18
an hour ago
- News18
UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Last Updated: With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore Uttar Pradesh's much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India's first bulk drug and formulation hub in Lalitpur. With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP's bid to become a national pharmaceutical manufacturing powerhouse. Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government's move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse. Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun. UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. 'Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said. The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players. Maheshwari described the park as a 'state-of-the-art plug-and-play facility" tailored to meet global standards. 'All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said. The park's underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency. Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises. Investor Incentives UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players. 'Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari. The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years. In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months. Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape. Strong Connectivity The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away). The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state's broader goal of becoming a $1 trillion economy. According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam. top videos View all 'We're not just matching global standards — we're aiming to surpass them," he said. 'Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we're ready to take the lead in pharma manufacturing." With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India's premier bulk drug manufacturing hub. First Published: News india UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
